Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 12/20 | 0.39 |
| ▸ | CCND1 | P24385 | 11/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.39 |
| ▸ | CDK4 | P11802 | 3/20 | 0.38 |
| ▸ | CCND2 | P30279 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18638030 | 1.00 | MAPK8 (0.45) | MAPK8MAPK10MAPK9MAPK14GSK3A | |
| SCHEMBL18637774 | 0.91 | CCND1 (0.44) | MAPK8CDK2CCND1CCNE1CDK6 | |
| SCHEMBL25950600 | 0.80 | MAPK8 (0.46) | MAPK8MAPK10MAPK9MAPK14CDK2 | |
| SCHEMBL18637985 | 0.80 | MAPK8 (0.52) | MAPK8MAPK10MAPK9MAPK14GSK3A | |
| SCHEMBL15298054 | 0.80 | MAPK8 (0.52) | MAPK8MAPK10MAPK9MAPK14GSK3A | |
| SCHEMBL15298252 | 0.79 | CDK2 (0.56) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL18638036 | 0.79 | CDK2 (0.56) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL17540002 | 0.76 | MAPK8 (0.52) | MAPK8MAPK10MAPK9MAPK14GSK3A | |
| SCHEMBL15298076 | 0.75 | MAPK8 (0.47) | MAPK8MAPK10MAPK9MAPK14GSK3A | |
| SCHEMBL18638034 | 0.75 | MAPK8 (0.47) | MAPK8MAPK10MAPK9MAPK14GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-9260442-B2 | Lactam kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260442-B2 | Lactam kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275066-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275066-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271460-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271460-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | MAPK8 1583/4885MAPK10 1684/4885MAPK9 1698/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | MAPK8 1326/4885MAPK10 1559/4885MAPK9 1996/4885 |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | CDK6, CCNC, MCL1 | MAPK8 965/4885MAPK10 1066/4885MAPK9 522/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | MAPK8 965/4885MAPK10 1066/4885MAPK9 522/4885 |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | RB1, CDK4, CDKN1A | MAPK8 1583/4885MAPK10 1684/4885MAPK9 1698/4885 |
| US-20140271460-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | MKI67, PCNA, HRAS | MAPK8 1326/4885MAPK10 1559/4885MAPK9 1996/4885 |
| US-20140275066-A1 | Transient Protection of Normal Cells During Chemotherapy | CDK6, CCNC, MCL1 | MAPK8 965/4885MAPK10 1066/4885MAPK9 522/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | MAPK8 1003/4885MAPK10 1060/4885MAPK9 847/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | MAPK8 1583/4885MAPK10 1684/4885MAPK9 1698/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | MAPK8 965/4885MAPK10 1066/4885MAPK9 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.